Iron status during anti-TNF therapy in children with juvenile idiopathic arthritis

Kristiina Aalto1, Visa Honkanen, Pekka Lahdenne

  • 1Helsinki University Central Hospital, University of Helsinki, Helsinki, HUS, Finland. kristiina.aalto@hus.fi

Clinical Rheumatology
|October 1, 2010
PubMed

Insights

Anti-tumor necrosis factor (TNF) therapy improved hemoglobin and iron status in children with juvenile idiopathic arthritis (JIA). Serum transferrin receptor (sTfR) and TfR/log ferritin index (TfR/logF) are useful for assessing iron deficiency in these patients.

Area of Science:

  • Pediatric Rheumatology
  • Hematology
  • Immunology

Background:

  • Patients with active juvenile idiopathic arthritis (JIA) often experience low hemoglobin (Hgb) due to chronic inflammation and/or iron deficiency.
  • Assessing iron status in JIA patients can be challenging due to inflammatory effects on iron markers.

Purpose of the Study:

  • To evaluate the impact of anti-tumor necrosis factor (TNF) therapy on the iron status of children with active JIA.
  • To determine the efficacy of anti-TNF agents in improving anemia and iron parameters in JIA.

Main Methods:

  • A cohort of twenty children with JIA received either etanercept (n=8) or infliximab (n=12) for 12 months.
  • Iron status was monitored using hemoglobin (Hgb), mean corpuscular volume (MCV), serum iron (sFe), ferritin, transferrin saturation (sTrfesat), and serum transferrin receptor (sTfR).
  • The sTfR/log ferritin index (TfR/logF) was calculated to further assess iron deficiency.

Main Results:

  • Anti-TNF therapy led to significant improvements in Hgb and MCV without iron supplementation.
  • Serum iron (sFe) and transferrin saturation (sTrfesat) levels increased from low to normal ranges.
  • Inflammation markers decreased, and serum transferrin receptor (sTfR) and TfR/logF were identified as reliable indicators of iron deficiency in this context.

Conclusions:

  • Anti-TNF therapy effectively improves anemia and iron status in children with active JIA.
  • Traditional iron deficiency markers (sFe, sTrfesat) may be unreliable in the presence of inflammation.
  • Serum transferrin receptor (sTfR) and the TfR/logF index are valuable tools for diagnosing iron deficiency in JIA patients undergoing anti-TNF treatment.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Autoimmune Disorders01:29

Autoimmune Disorders

Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune system...
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...